Despite two decades of use, there are limited data on the best way to administer and monitor cyclosporine for orthotopic liver transplantation. The present study was undertaken among 130 consecutive liver transplant cases undergone operation since 1993 till 2004 in Shiraz (Southern Iran) Organ Transplant Center to determine if induction of immune suppression with oral cyclosporine will improve the results of liver transplantation and decrease toxicity. The operative procedure included either piggyback technique or Veno-venous bypass in the rest. All cases were first transplants. Immunosuppressive regimen included Celcept, cyclosporine and methylprednisolone for nearly all the patients. IV cyclosporine was used for induction in the first 39 cases and since then (for the remaining 61 cases) enteral preparation (neoral) has been _used. Mean cyclosporine dose was 125 mg and C2 monitoring was performed for every patient. There were no differences between the two groups with respect to patient survival, graft survival or rejection-free survival. However, renal problems and neurologic manifestations occurred less frequently in the oral route group (p<0.05). In summary, induction of immune suppression with oral cyclosporine did decrease complications but did not affect the survival or rejection rate.